ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.

Features

Auto Apply Resume Optimizer Cover Letter Optimizer Interview Prep

Company

Social Media

Need Help?

team@applyblast.com

Associate Director, Biologics Formulation Development at Dianthus Therapeutics - ApplyBlast

Associate Director, Biologics Formulation Development

Dianthus Therapeutics

4 months ago

Remote

Full Time

Senior

1 applicant

View Job Listing

Apply to 100+ jobs

About this role

Senior Formulation Development Leader for a New Bispecific Fusion Protein Program

Responsibilities

Lead formulation development strategy for a new bispecific fusion protein from preclinical stage through clinical development
Design and execute studies to assess protein stability, aggregation, degradation pathways, viscosity, and developability under relevant formulation conditions
Develop liquid and, where appropriate, lyophilized formulations to support both IV and SC presentations
Lead excipient screening, buffer optimization, pH optimization, surfactant selection, and stress stability studies to identify robust drug product formulations
Drive high-concentration formulation development for subcutaneous delivery, including syringeability, injectability, and device compatibility assessments

Skills

Qualifications

Ph.D. in Pharmaceutical Sciences, Chemistry, Chemical Engineering, Biochemistry, or a related fieldM.S. with 10+ years of relevant experience

About Dianthus Therapeutics

dianthustx.com

Headquarters

New York, New York, United States

Company Size

11-50 employees

View Profile

Dianthus Therapeutics is a biotechnology company focused on developing next‑generation antibody therapeutics that target the complement system to address diseases with high unmet medical need. The company engineers selective, potent complement‑modulating antibodies with the goal of improving safety and efficacy over existing therapies. Dianthus advances novel antibody candidates toward clinical development and is committed to translating complement biology into meaningful treatments for patients.